Cost-minimization analysis of recombinant factor VIII Fc versus emicizumab for treating patients with hemophilia A without inhibitors in Europe

References

• Gilbert GE. The evolving understanding of factor VIII binding sites and implications for the treatment of hemophilia A. Blood Rev. 2019;33:1–5.
   PubMed Web of Science ®Google Scholar
• National Hemophilia Foundation. Fast facts. 2020. [cited 2020 May]. Available from: https://www.hemophilia.org/About-Us/Fast-Facts.
   Google Scholar
• Berntorp E. Future of haemophilia outcome assessment: registries are key to optimized treatment. J Intern Med. 2016;279(6):498–501.
   PubMed Web of Science ®Google Scholar
• O'Hara J, Hughes D, Camp C, et al. The cost of severe haemophilia in Europe: the CHESS study. Orphanet J Rare Dis. 2017;12(1):106.
   PubMed Web of Science ®Google Scholar
• World Federation of Hemophilia. Complications of hemophilia. 2012. [cited 2020 April]; Available from: http://www1.wfh.org/publications/files/pdf-1499.pdf.
   Google Scholar
• Buckner TW, Batt K, Quon D, et al. Assessments of pain, functional impairment, anxiety, and depression in US adults with hemophilia across patient-reported outcome instruments in the pain, functional impairment, and quality of life (P-FiQ) study. Eur J Haematol. 2018;100(Suppl 1):5–13.
   PubMedGoogle Scholar
• Cavazza M, Kodra Y, Armeni P, et al. Social/economic costs and quality of life in patients with haemophilia in Europe. Eur J Health Econ. 2016;17(Suppl 1):53–65.
   PubMed Web of Science ®Google Scholar
• Poon J-L, Zhou Z-Y, Doctor JN, et al. Quality of life in haemophilia A: hemophilia utilization group study Va (HUGS-Va). Haemophilia. 2012;18(5):699–707.
   PubMed Web of Science ®Google Scholar
• Darby SC, Kan SW, Spooner RJ, et al. Mortality rates, life expectancy, and causes of death in people with hemophilia A or B in the United Kingdom who were not infected with HIV. Blood. 2007;110(3):815–825.
   PubMed Web of Science ®Google Scholar
• Lovdahl S, et al. Incidence, mortality rates and causes of deaths in haemophilia patients in Sweden. Haemophilia. 2013;19(3):362–369.
   PubMed Web of Science ®Google Scholar
• Aledort L, Mannucci PM, Schramm W, et al. Factor VIII replacement is still the standard of care in haemophilia A. Blood Transfus. 2019;17(6):479–486.
   PubMed Web of Science ®Google Scholar
• Efmoroctocog alfa for haemophilia A. Aust Prescr. 2018;41(6):200.
   PubMedGoogle Scholar
• European Medicines Agency. Elocta (rFVIIIFc) summary of product characteristics. 2019. [cited 2020 May]. Available from: https://www.ema.europa.eu/en/documents/product-information/elocta-epar-product-information_en.pdf.
   Google Scholar
• Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood. 2014;123(3):317–325.
   PubMed Web of Science ®Google Scholar
• Nolan B, Mahlangu J, Pabinger I, et al. Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: final results from the ASPIRE extension study. Haemophilia. 2020;26(3):494–502.
   PubMed Web of Science ®Google Scholar
• Young G, Mahlangu J, Kulkarni R, et al. Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A. J Thromb Haemost. 2015;13(6):967–977.
   PubMed Web of Science ®Google Scholar
• Hakimi Z, Santagostino E, Postma MJ, et al. Recombinant FVIIIFc versus Bay 94-9027 for treatment of patients with haemophilia A: comparative efficacy using a matching adjusted indirect comparison. Adv Ther. 2021;38(2):1263–1274.
   PubMed Web of Science ®Google Scholar
• Henry N, Jovanović J, Schlueter M, et al. Cost-utility analysis of life-long prophylaxis with recombinant factor VIIIFc vs recombinant factor VIII for the management of severe hemophilia A in Sweden. J Med Econ. 2018;21(4):318–325.
   PubMed Web of Science ®Google Scholar
• Bullement A, McMordie ST, Hatswell AJ, et al. Cost-effectiveness analysis of recombinant factor VIII Fc-fusion protein (rFVIIIFc) for the treatment of severe hemophilia A in Italy incorporating real-world dosing and joint health data. Pharmacoecon Open. 2020;4(1):133–142.
   PubMed Web of Science ®Google Scholar
• Blair HA. Emicizumab: a review in haemophilia A. Drugs. 2019;79(15):1697–1707.
   PubMed Web of Science ®Google Scholar
• Knight T, Callaghan MU. The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A. Ther Adv Hematol. 2018;9(10):319–334.
   PubMed Web of Science ®Google Scholar
• Roche Pharma AG. Hemlibra® summary of product characteristics. 2019. [cited 2020 March]. Available from: https://www.ema.europa.eu/en/documents/product-information/hemlibra-epar-product-information_en.pdf.
   Google Scholar
• Klamroth R, Wojciechowski P, Aballéa S, et al. Efficacy of rFVIIIFc versus emicizumab for the treatment of patients with hemophilia A without inhibitors: Matching-adjusted indirect comparison of A-LONG and HAVEN trials. J Blood Med. 2021;12:115–122.
   PubMed Web of Science ®Google Scholar
• Genentech. Hemlibra dosing calculator. 2020. [cited 2020 March]. Available from: https://www.hemlibra.com/hcp/dosing-administration/dosing-calculator.html.
   Google Scholar
• Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med. 2018;379(9):811–822.
   PubMed Web of Science ®Google Scholar
• Pipe SW, Shima M, Lehle M, et al. Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol. 2019;6(6):e295–e305.
   PubMed Web of Science ®Google Scholar
• KL R. Essentials of pharmacoeconomics. Chapter 4. Philadelphia (PA): Lippincott Williams & Wilkins; 2009.
   Google Scholar
• Buckley B, Dreyfus J, Prasad M, et al. Burden of illness and costs among paediatric haemophilia patients with and without central venous access devices treated in US hospitals. Haemophilia. 2018;24(3):e93–e102.
   PubMed Web of Science ®Google Scholar
• Cafe A, Carvalho M, Crato M, et al. Haemophilia A: health and economic burden of a rare disease in Portugal. Orphanet J Rare Dis. 2019;14(1):211.
   PubMed Web of Science ®Google Scholar
• Carlos-Rivera F, Gasca-Pineda R, Majluf-Cruz A, et al. Economic impact of hemophilia type A and B in Mexico. Gac Med Mex. 2016;152(1):19–29.
   PubMed Web of Science ®Google Scholar
• Castro Jaramillo HE, Viscaya MM, Mejia AE. Cost-utility analysis of primary prophylaxis, compared with on-demand treatment, for patients with severe hemophilia type A in Colombia. Int J Technol Assess Health Care. 2016;32(5):337–347.
   PubMed Web of Science ®Google Scholar
• Colombo GL, Di Matteo S, Mancuso ME, et al. Cost-utility analysis of prophylaxis versus treatment on demand in severe hemophilia A. Clinicoecon Outcomes Res. 2011;3:55–61.
   PubMedGoogle Scholar
• Coppola A, D'Ausilio A, Aiello A, et al. Cost-effectiveness analysis of late prophylaxis vs. on-demand treatment for severe haemophilia A in Italy. Haemophilia. 2017;23(3):422–429.
   PubMed Web of Science ®Google Scholar
• Cortesi PA, D'Angiolella LS, Lafranconi A, et al. Modern treatments of haemophilia: review of cost-effectiveness analyses and future directions. Pharmacoeconomics. 2018;36(3):263–284.
   PubMed Web of Science ®Google Scholar
• Gharibnaseri Z, Davari M, Cheraghali A, et al. Health care resource utilization and cost of care for haemophilia A and B patients in Iran. Transfus Apher Sci. 2016;54(1):122–126.
   PubMed Web of Science ®Google Scholar
• Jadhav U, Mukherjee K. Assessment of healthcare measures, healthcare resource use, and cost of care among severe hemophilia A patients in Mumbai region of India. J Postgrad Med. 2018;64(3):138–144.
   PubMed Web of Science ®Google Scholar
• Kodra Y, Cavazza M, Schieppati A, et al. The social burden and quality of life of patients with haemophilia in Italy. Blood Transfus. 2014;12(Suppl 3):s567–s575.
   PubMed Web of Science ®Google Scholar
• Lorenzoni V, Triulzi I, Turchetti G. Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia A: the Italian national health system perspective. BMC Health Serv Res. 2018;18(1):596.
   PubMed Web of Science ®Google Scholar
• Patel AM, Corman SL, Chaplin S, et al. Economic impact model of delayed inhibitor development in patients with hemophilia A receiving emicizumab for the prevention of bleeding events. J Med Econ. 2019;22(12):1328–1337.
   PubMed Web of Science ®Google Scholar
• Pattanaprateep O, Chuansumrit A, Kongsakon R. Cost-utility analysis of home-based care for treatment of Thai hemophilia A and B. Value Health Reg Issues. 2014;3:73–78.
   PubMedGoogle Scholar
• Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe, clinically effective, patient preferred, and cost saving. Healthcare. 2017;5(1–2):68–80.
   Web of Science ®Google Scholar
• Shrestha A, Eldar-Lissai A, Hou N, et al. Real-world resource use and costs of haemophilia A-related bleeding. Haemophilia. 2017;23(4):e267–e275.
   PubMed Web of Science ®Google Scholar
• Thorat T, Neumann PJ, Chambers JD. Hemophilia burden of disease: a systematic review of the cost-utility literature for hemophilia. JMCP. 2018;24(7):632–642.
   PubMed Web of Science ®Google Scholar
• Agency EM. Advate summary of product characteristics. 2018. [cited 2022 June]. Available from: https://www.ema.europa.eu/en/documents/product-information/advate-epar-product-information_en.pdf.
   Google Scholar
• Cortesi PA, Castaman G, Trifirò G, et al. Cost-effectiveness and budget impact of emicizumab prophylaxis in haemophilia A patients with inhibitors. Thromb Haemost. 2020;120(2):216–228.
   PubMed Web of Science ®Google Scholar
• Lee H, Cho H, Han JW, et al. Cost-utility analysis of emicizumab prophylaxis in haemophilia A patients with factor VIII inhibitors in Korea. Haemophilia. 2021;27(1):e12–e21.
   PubMed Web of Science ®Google Scholar
• Polack B, Trossaërt M, Cousin M, et al. Cost-effectiveness of emicizumab vs bypassing agents in the prevention of bleeding episodes in haemophilia A patients with anti-FVIII inhibitors in France. Haemophilia. 2021;27(1):e1–e11.
   PubMed Web of Science ®Google Scholar
• Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947.
   PubMed Web of Science ®Google Scholar